BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Therapeutic Solutions Utilizes MSC Exosomes to Suppress Inflammatory Pathologies
Therapeutic Solutions MSC exosomes

Therapeutic Solutions Utilizes MSC Exosomes to Suppress Inflammatory Pathologies

October 18, 2021 By Cade Hildreth (CEO) Leave a Comment

  • Therapeutic Solutions International Utilizes Mesenchymal Stem Cell Exosomes to Effectively Suppress Neutrophil Extracellular Trap Production
  • Patent Filed on Potential Solution to Cause of Major Inflammatory Pathologies

ELK CITY, Idaho, Oct. 4, 2021 — Therapeutic Solutions International, Inc., (OTC Markets: TSOI) announced laboratory data demonstrating that exosomes produced by JadiCells™, the Company’s Phase III cell therapy candidate for COVID-19 and other lung pathology, as well as mesenchymal stem cells proprietary to the Company, can suppress the production of neutrophil extracellular traps.

Discover class-defining bioproduction tools.

Neutrophil extracellular traps are a network of extracellular DNA, histones, and enzymes that cause inflammation. In healthy individuals, neutrophil extracellular traps are very useful in fighting bacterial infections. Unfortunately, in conditions such as COVID-19, atherosclerosis, cancer, and various autoimmune diseases, neutrophil extracellular traps are considered to play a major role in disease initiation and progression1.

In a series of experiments JadiCells and other mesenchymal stem cells were stimulated using agents that replicate biological “danger signals”.  It was observed that the cells produced exosomes, which when added to neutrophils, would inhibit the production of neutrophil extracellular traps. The experimental data is part of a patent application that was submitted today.

“Due to the small size of exosomes, their ease of production, and the fact that they are made from stem cells that are recognized by the FDA, we anticipate rapid translation of this new approach into potential treatments for a variety of inflammation associated conditions,” said Dr. James Veltmeyer, Chief Medical Officer of the Company. “Preliminary data suggests that the exosomes themselves possess potent lung protective activity in animal models of lung injury simple to COVID-19. This gets us excited because it opens the possibility for increasing our product pipeline.”

Rooster DevServices

“The lifeblood of our Company is the germination of thought into working applications. The findings described today are particularly exciting to us because they point to a potentially new mechanism by which stem cells, and the exosomes they produce, affect inflammation,” said Timothy Dixon, President and CEO of the Company and co-inventor. “By targeting broadly acting molecular targets we have the opportunity to develop First in Class approaches towards diseases, which have significant possibility of sale or partnership with Big Pharma.”

1. Jorge and Kubes. An emerging role for neutrophil extracellular traps in noninfectious disease.  Nat Med. 2017 Mar 7;23(3):279-287

bitbio
To learn more about the rapidly expanding exosome market, view the “Global Exosome Market – Market Size, Forecast, Trials and Trends, 2021.”

Exosome market report

5/5 - (2 votes)

Filed Under: Exosomes, MSCs, Press Releases, Stem Cell News

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Featured Posts

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

iPSC derived cell therapeutics

The Pipeline for iPSC-Derived Cell Therapeutics in 2022

Stem cell companies

List of Stem Cell Companies Worldwide (2022)

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.